Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment

NCT01628107 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01628107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01628107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 16, 2012
Completion date
January 2, 2015
Enrollment
406 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure requiring hemodialysis